PriceTargets.com logo

NASDAQ:IMAC - IMAC Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $2.35
  • Forecasted Upside: 12.98 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.08 As of 06/24/2021 04:59 PM ET
▼ -0.02 (-0.95%)

This chart shows the closing price for IMAC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New IMAC Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IMAC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IMAC

Analyst Price Target is $2.35
▲ +12.98% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for IMAC in the last 3 months. The average price target is $2.35, with a high forecast of $2.35 and a low forecast of $2.35. The average price target represents a 12.98% upside from the last price of $2.08.

This chart shows the closing price for IMAC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in IMAC. This rating has held steady since March 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/31/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/30/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/28/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/26/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/25/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/9/2021Alliance Global PartnersLower Price TargetPositive ➝ Buy$3.10 ➝ $2.35Low
11/17/2020Alliance Global PartnersInitiated CoverageBuy$2.75Low
4/15/2020Ascendiant Capital MarketsInitiated CoverageBuy$4.50Medium
1/14/2020Dawson JamesReiterated RatingBuy ➝ NeutralLow
(Data available from 6/24/2016 forward)
IMAC logo
IMAC Holdings, Inc. provides orthopedic therapies through a chain of innovative medical advancements and care regeneration centers in the United States. Its outpatient medical clinics provide regenerative, orthopedic, and minimally invasive procedures and therapies to patients with sports injuries, ligament and tendon damage, and other related soft tissue conditions, as well as back, knee, and joint pains. As of December 31, 2020, the company operated 16 outpatient clinics in Kentucky, Missouri, Tennessee, Illinois, and Florida. IMAC Holdings, Inc. was founded in 2000 and is based in Brentwood, Tennessee.
Read More

Today's Range

Now: $2.08
Low: $2.07
High: $2.09

50 Day Range

MA: $1.83
Low: $1.49
High: $2.27

52 Week Range

Now: $2.08
Low: $0.64
High: $2.75

Volume

5,225 shs

Average Volume

464,506 shs

Market Capitalization

$52.42 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of IMAC?

The following Wall Street research analysts have issued research reports on IMAC in the last twelve months: Alliance Global Partners, and Zacks Investment Research.
View the latest analyst ratings for IMAC.

What is the current price target for IMAC?

1 Wall Street analysts have set twelve-month price targets for IMAC in the last year. Their average twelve-month price target is $2.35, suggesting a possible upside of 13.0%. Alliance Global Partners has the highest price target set, predicting IMAC will reach $2.35 in the next twelve months. Alliance Global Partners has the lowest price target set, forecasting a price of $2.35 for IMAC in the next year.
View the latest price targets for IMAC.

What is the current consensus analyst rating for IMAC?

IMAC currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IMAC will outperform the market and that investors should add to their positions of IMAC.
View the latest ratings for IMAC.

What other companies compete with IMAC?

Other companies that are similar to IMAC include Acadia Healthcare, Hanger, Aesthetic Medical International Holdings Group, BioCorRx, Ceres Ventures and AAC.

How do I contact IMAC's investor relations team?

IMAC's physical mailing address is 1605 WESTGATE CIRCLE, BRENTWOOD TN, 37027. The company's listed phone number is 844-266-4622 and its investor relations email address is [email protected] The official website for IMAC is www.imacregeneration.com.